Genuinely effective obesity drugs, as GLP-1s appear to be, should have a positive impact on the bottom line of US health insurers like Cigna (CI), United Healthcare (UNH), Humana (HUM) and Centene (CNC) in the long term while harming companies paying for these very expensive and likely to be in-demand medications like Insperity (NSP) and Robert Half (RHI)
When taken together, especially if an individual is also on other glucose-lowering medications (like sulfonylureas or insulin), the risk of hypoglycemia (low blood sugar) can increase
We never sell your information
By activating GLP-1 receptors, these medications help to slow gastric emptying, increase insulin secretion, and promote a feeling of fullness, all of which contribute to reduced calorie intake and weight loss
This has led to the false assumption that the cause of GSH depletion associated with so many chronic diseases must be from an under supply of cysteine in the diet